Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab.

IF 5 2区医学 Q1 OPHTHALMOLOGY

Investigative ophthalmology & visual science Pub Date : 2024-09-03 DOI:10.1167/iovs.65.11.15

Takahito Todoroki, Jun Takeuchi, Hikaru Ota, Yuyako Nakano, Ai Fujita Sajiki, Koichi Nakamura, Hiroki Kaneko, Koji M Nishiguchi

{"title":"Aqueous Humor Cytokine Analysis in Age-Related Macular Degeneration After Switching From Aflibercept to Faricimab.","authors":"Takahito Todoroki, Jun Takeuchi, Hikaru Ota, Yuyako Nakano, Ai Fujita Sajiki, Koichi Nakamura, Hiroki Kaneko, Koji M Nishiguchi","doi":"10.1167/iovs.65.11.15","DOIUrl":null,"url":null,"abstract":"Purpose: To examine the changes in aqueous humor cytokine levels and clinical outcomes of switching from aflibercept to faricimab in eyes with neovascular age-related macular degeneration (nAMD).Methods: Fifty-four eyes of 54 patients with AMD undergoing treatment with aflibercept under a treat-and-extend (TAE) regimen were switched to faricimab and studied prospectively. Best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution), central retinal thickness (CRT), central choroidal thickness (CCT), and exudative status were analyzed using optical coherence tomography. Aqueous humor was collected before and after the switch, and angiopoietin-2 (Ang-2), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) A levels were measured.Results: After switching from aflibercept to faricimab, exudative changes improved in 28 eyes (52%), remained stable in eight eyes (15%), and worsened in 18 eyes (33%). BCVA changed from 0.27 ± 0.31 to 0.26 ± 0.29 (P = 0.46), CRT decreased from 306.2 ± 147.5 µm to 278.6 ± 100.4 µm (P = 0.11), and CCT changed from 189.5 ± 92.8 µm to 186.8 ± 93.9 µm (P = 0.21). VEGF-A levels were below the detection sensitivity in many cases throughout the pre- and post-switching periods. Ang-2 significantly decreased from 23.8 ± 23.5 pg/mL to 16.4 ± 21.9 pg/mL (P < 0.001), and PlGF significantly increased from 0.86 ± 0.85 pg/mL to 1.72 ± 1.39 pg/mL (P < 0.001).Conclusions: Switching from aflibercept to faricimab in patients with nAMD may not only suppress VEGF-A but also Ang-2 and reduce exudative changes.","PeriodicalId":14620,"journal":{"name":"Investigative ophthalmology & visual science","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11385661/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Investigative ophthalmology & visual science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1167/iovs.65.11.15","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To examine the changes in aqueous humor cytokine levels and clinical outcomes of switching from aflibercept to faricimab in eyes with neovascular age-related macular degeneration (nAMD).

Methods: Fifty-four eyes of 54 patients with AMD undergoing treatment with aflibercept under a treat-and-extend (TAE) regimen were switched to faricimab and studied prospectively. Best-corrected visual acuity (BCVA; in logarithm of the minimum angle of resolution), central retinal thickness (CRT), central choroidal thickness (CCT), and exudative status were analyzed using optical coherence tomography. Aqueous humor was collected before and after the switch, and angiopoietin-2 (Ang-2), placental growth factor (PlGF), and vascular endothelial growth factor (VEGF) A levels were measured.

Results: After switching from aflibercept to faricimab, exudative changes improved in 28 eyes (52%), remained stable in eight eyes (15%), and worsened in 18 eyes (33%). BCVA changed from 0.27 ± 0.31 to 0.26 ± 0.29 (P = 0.46), CRT decreased from 306.2 ± 147.5 µm to 278.6 ± 100.4 µm (P = 0.11), and CCT changed from 189.5 ± 92.8 µm to 186.8 ± 93.9 µm (P = 0.21). VEGF-A levels were below the detection sensitivity in many cases throughout the pre- and post-switching periods. Ang-2 significantly decreased from 23.8 ± 23.5 pg/mL to 16.4 ± 21.9 pg/mL (P < 0.001), and PlGF significantly increased from 0.86 ± 0.85 pg/mL to 1.72 ± 1.39 pg/mL (P < 0.001).

Conclusions: Switching from aflibercept to faricimab in patients with nAMD may not only suppress VEGF-A but also Ang-2 and reduce exudative changes.

查看原文本刊更多论文

从阿弗利贝赛转换到法利单抗后年龄相关性黄斑变性的眼液细胞因子分析。

目的：研究新生血管性年龄相关性黄斑变性（nAMD）患者从阿弗利百普转用法利单抗后，眼液细胞因子水平的变化和临床疗效：54名AMD患者中的54只眼睛接受了阿弗利百普治疗，并在治疗和延长（TAE）方案下转用了法尼单抗，并进行了前瞻性研究。使用光学相干断层扫描分析了最佳矫正视力（BCVA；最小分辨角的对数）、视网膜中央厚度（CRT）、脉络膜中央厚度（CCT）和渗出状态。在换药前后收集了眼房水，并测量了血管生成素-2（Ang-2）、胎盘生长因子（PlGF）和血管内皮生长因子（VEGF）A的水平：从阿弗利贝赛转换为法替单抗后，28只眼睛（52%）的渗出性变化有所改善，8只眼睛（15%）保持稳定，18只眼睛（33%）恶化。BCVA从0.27 ± 0.31变为0.26 ± 0.29（P = 0.46），CRT从306.2 ± 147.5 µm变为278.6 ± 100.4 µm（P = 0.11），CCT从189.5 ± 92.8 µm变为186.8 ± 93.9 µm（P = 0.21）。在转换前后的整个过程中，许多病例的 VEGF-A 水平都低于检测灵敏度。Ang-2从23.8 ± 23.5 pg/mL显著降至16.4 ± 21.9 pg/mL（P < 0.001），PlGF从0.86 ± 0.85 pg/mL显著增至1.72 ± 1.39 pg/mL（P < 0.001）：nAMD患者从阿弗利贝赛转用法替单抗不仅可以抑制VEGF-A，还可以抑制Ang-2，减少渗出性改变。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Investigative ophthalmology & visual science 医学-眼科学

CiteScore

6.90

自引率

4.50%

发文量

339

审稿时长

1 months

期刊介绍： Investigative Ophthalmology & Visual Science (IOVS), published as ready online, is a peer-reviewed academic journal of the Association for Research in Vision and Ophthalmology (ARVO). IOVS features original research, mostly pertaining to clinical and laboratory ophthalmology and vision research in general.